StockData
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31

VERACYTE, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$43.80+0.68 (+1.58%)

Close on Oct 19, 2026

Market cap
$3.59B
P/E (TTM)
31.3
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026During market hours$150.30M$0.31$0.54
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026During market hours$139.10M$0.35$0.52
Q4 FY2025
Ended Dec 31, 2025
Jan 12, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025During market hours$131.90M$0.24$0.51
Q2 FY2025
Ended Jun 30, 2025
Aug 6, 2025During market hours$130.20M$-0.01$0.44
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025During market hours$114.50M$0.09$0.31
Q4 FY2024
Ended Dec 31, 2024
Feb 24, 2025During market hours$118.60M$0.06$0.36
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024During market hours$115.90M$0.19$0.33
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024During market hours$114.40M$0.07$0.30
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Jan 8, 2024Before market open–––

Company guidance

Outlook given with results on Jul 30, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
adjusted EBITDA marginnon-GAAP202626%New
testing revenue growth202617% to 18% growthNew
testing revenue2026$576.00M to $582.00MNew
total revenue growth202614% to 15% growthLowered
total revenue2026$590.00M to $596.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Veracyte filed with the SEC